$ACUR Free Research Reports on ACUR, BIIB, HO
Post# of 29744
Posted On: 12/11/2012 10:09:45 AM
$ACUR
Free Research Reports on ACUR, BIIB, HON and MCP Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) shares of the biotech company soared over 740 percent on nearly 3 million shares traded Monday. The company has recently announced the launch of Nexafed, which disrupts the conversion of Pseudoephedrine into the dangerous drug, methamphetamine.
Find out more about Acura Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ACUR
Biogen Idec Inc. (NASDAQ: BIIB) shares have gained nearly 40 percent year-to-date. The company has recently entered into a partnership with ISIS Pharmaceuticals for the discovery and development of antisense drugs.
Find out more about Biogen Idec including full access to the free equity report at: www.BedfordReport.com/BIIB
Honeywell International Inc. (NYSE: HON) shares have gained nearly 15 percent year-to-date. The company recently agreed to purchase Intermec for approximately $600 million.
Find out more about Honeywell including full access to the free equity report at: www.BedfordReport.com/HON
Molycorp Inc. (NYSE: MCP) shares rallied 20 percent on over three times the average daily volume Monday. The company remains on pace to achieve a Phase 1 operational rate of 19,050 metric tons per year at its Mountain Pass facility in the fourth quarter of 2012.
Find out more about Molycorp including full access to the free equity report at: www.BedfordReport.com/MCP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.
Contact Information:
Equity News Circuit
Email Contact
Free Research Reports on ACUR, BIIB, HON and MCP Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) shares of the biotech company soared over 740 percent on nearly 3 million shares traded Monday. The company has recently announced the launch of Nexafed, which disrupts the conversion of Pseudoephedrine into the dangerous drug, methamphetamine.
Find out more about Acura Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ACUR
Biogen Idec Inc. (NASDAQ: BIIB) shares have gained nearly 40 percent year-to-date. The company has recently entered into a partnership with ISIS Pharmaceuticals for the discovery and development of antisense drugs.
Find out more about Biogen Idec including full access to the free equity report at: www.BedfordReport.com/BIIB
Honeywell International Inc. (NYSE: HON) shares have gained nearly 15 percent year-to-date. The company recently agreed to purchase Intermec for approximately $600 million.
Find out more about Honeywell including full access to the free equity report at: www.BedfordReport.com/HON
Molycorp Inc. (NYSE: MCP) shares rallied 20 percent on over three times the average daily volume Monday. The company remains on pace to achieve a Phase 1 operational rate of 19,050 metric tons per year at its Mountain Pass facility in the fourth quarter of 2012.
Find out more about Molycorp including full access to the free equity report at: www.BedfordReport.com/MCP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.
A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.
Contact Information:
Equity News Circuit
Email Contact
(0)
(0)